Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $310.00

Posted by Francis Steltz on Nov 3rd, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price target upped by investment analysts at JPMorgan Chase & Co. from $300.00 to $310.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 34.23% from the stock’s previous close.

A number of other analysts also recently issued reports on the company. Barclays lifted their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday. Needham & Company LLC raised their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research report on Tuesday. Weiss Ratings cut Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, October 28th. Finally, Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $293.45.

Check Out Our Latest Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock Up 7.7%

NASDAQ JAZZ traded up $16.50 during trading hours on Tuesday, hitting $230.94. 783,904 shares of the company were exchanged, compared to its average volume of 930,050. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The firm has a market cap of $14.99 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 0.41 and a beta of 0.38. The company has a 50 day moving average of $231.16 and a two-hundred day moving average of $216.50. Jazz Pharmaceuticals has a 52-week low of $128.80 and a 52-week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.05) by $0.17. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned $8.13 earnings per share. Equities research analysts anticipate that Jazz Pharmaceuticals will post 10.87 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Robert Iannone sold 76,921 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total value of $472,800.00. Following the completion of the sale, the chief executive officer directly owned 141,394 shares of the company’s stock, valued at approximately $33,425,541.60. This trade represents a 1.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 94,121 shares of company stock worth $23,337,922. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the company. Pictet Asset Management Holding SA increased its holdings in shares of Jazz Pharmaceuticals by 1.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 149,115 shares of the specialty pharmaceutical company’s stock valued at $34,640,000 after acquiring an additional 1,516 shares during the period. Pegasus Asset Management Inc. acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth $3,664,000. AlphaCentric Advisors LLC grew its position in Jazz Pharmaceuticals by 29.8% during the 3rd quarter. AlphaCentric Advisors LLC now owns 4,688 shares of the specialty pharmaceutical company’s stock worth $1,085,000 after purchasing an additional 1,075 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Jazz Pharmaceuticals during the 3rd quarter worth $225,000. Finally, Calamos Advisors LLC grew its position in Jazz Pharmaceuticals by 764.2% during the 3rd quarter. Calamos Advisors LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $2,863,000 after purchasing an additional 10,935 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

Positive Sentiment: Q3 results beat expectations: Jazz reported revenue of approximately $1.24 billion, up 10.4% year over year and above the $1.21 billion consensus estimate. Its adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Positive Sentiment: Full-year outlook increased: Management raised 2026 revenue guidance to roughly $4.78 billion-$4.90 billion, above Wall Street expectations of about $4.7 billion. Growth is being supported by oncology products and rare-sleep medicines, including 12% year-over-year Xywav revenue growth and 425 net patient additions during the quarter. JAZZ Q3 Earnings and Sales Beat Estimates
Positive Sentiment: Analyst sentiment improved: Morgan Stanley raised its target to $319 and maintained an “overweight” rating, while RBC lifted its target to $305 with an “outperform” rating. Barclays also increased its target to $275 and retained an “overweight” rating, signaling continued confidence in Jazz’s earnings outlook. Morgan Stanley Jazz Pharmaceuticals Rating
Positive Sentiment: Pipeline and product catalysts: Ziihera has launched in first-line HER2-positive metastatic gastric or esophageal cancer, with projected peak sales potential of $3 billion-$5 billion. Jazz also completed its Actio acquisition and plans to present neuro-oncology data, including Phase 3 ACTION trial progress, at the upcoming SNO meeting. Jazz Ziihera Revenue Guidance
Neutral Sentiment: JAZZ was among pharmaceutical stocks showing unusually high options volume, indicating increased trading interest but not necessarily a clear directional signal. Biotech Stocks Seeing Unusual Options Volume
Negative Sentiment: The quarter still produced a loss compared with $8.13 per share of earnings a year earlier, and commentary has raised concerns about slowing growth and charges associated with the Actio acquisition. These issues could temper the upside despite the stronger guidance. Jazz Pharmaceuticals Earnings and Guidance Analysis

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.